Cet anticorps Lapin Polyclonal détecte spécifiquement LEF1 dans WB et IF. Il présente une réactivité envers Humain et a été mentionné dans 1 publication.
This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogène
This LEF1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 10-37 amino acids from the N-terminal region of human LEF1.
LEF1
Reactivité: Humain, Souris, Rat
WB, ELISA, IHC, IF, ICC
Hôte: Lapin
Polyclonal
unconjugated
Indications d'application
IF: 1:10~50. WB: 1:2000. WB: 1:2000. WB: 1:1000
Restrictions
For Research Use only
Format
Liquid
Buffer
Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
4 °C,-20 °C
Stockage commentaire
Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
Date de péremption
6 months
Yao, Li, Liang, Lu, Zhu, Liu, Zhang, Yuan, Wang: "Methylprednisolone suppresses the Wnt signaling pathway in chronic lymphocytic leukemia cell line MEC-1 regulated by LEF-1 expression." dans: International journal of clinical and experimental pathology, Vol. 8, Issue 7, pp. 7921-8, (2015) (PubMed).
Antigène
LEF1
(Lymphoid Enhancer-Binding Factor 1 (LEF1))
Autre désignation
LEF1
Sujet
This gene encodes a transcription factor belonging to a family of proteins that share homology with the high mobility group protein-1. The protein encoded by this gene can bind to a functionally important site in the T-cell receptor-alpha enhancer, thereby conferring maximal enhancer activity. This transcription factor is involved in the Wnt signaling pathway, and it may function in hair cell differentiation and follicle morphogenesis. Mutations in this gene have been found in somatic sebaceous tumors. This gene has also been linked to other cancers, including androgen-independent prostate cancer. Alternative splicing results in multiple transcript variants.